Raymond James & Associates Takes Position in Acelyrin, Inc. (NASDAQ:SLRN)

Raymond James & Associates acquired a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRNFree Report) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 18,556 shares of the company’s stock, valued at approximately $189,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Osaic Holdings Inc. purchased a new position in shares of Acelyrin during the 2nd quarter valued at $25,000. Tower Research Capital LLC TRC bought a new position in shares of Acelyrin during the 2nd quarter valued at about $64,000. Zimmer Partners LP bought a new position in shares of Acelyrin during the 2nd quarter valued at about $251,000. Bank of New York Mellon Corp bought a new position in shares of Acelyrin during the 2nd quarter valued at about $276,000. Finally, Landscape Capital Management L.L.C. bought a new position in shares of Acelyrin during the 2nd quarter valued at about $322,000. Institutional investors own 94.68% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on SLRN. Wells Fargo & Company initiated coverage on Acelyrin in a research report on Wednesday, December 13th. They set an “equal weight” rating and a $11.00 price objective on the stock. Citigroup initiated coverage on Acelyrin in a report on Friday, December 8th. They set a “neutral” rating and a $8.00 target price for the company. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Acelyrin in a report on Tuesday, November 28th. Morgan Stanley dropped their target price on Acelyrin from $19.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, November 29th. Finally, Jefferies Financial Group dropped their target price on Acelyrin from $15.00 to $12.00 and set a “buy” rating for the company in a report on Tuesday, November 28th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $23.67.

View Our Latest Report on Acelyrin

Acelyrin Trading Down 1.4 %

NASDAQ SLRN opened at $7.79 on Thursday. Acelyrin, Inc. has a fifty-two week low of $5.70 and a fifty-two week high of $29.88. The stock has a 50 day simple moving average of $7.20 and a two-hundred day simple moving average of $12.80.

Acelyrin (NASDAQ:SLRNGet Free Report) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.40). On average, sell-side analysts expect that Acelyrin, Inc. will post -7.4 earnings per share for the current year.

Insider Transactions at Acelyrin

In other Acelyrin news, CEO Shao-Lee Lin sold 10,691 shares of Acelyrin stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $7.41, for a total value of $79,220.31. Following the completion of the sale, the chief executive officer now owns 1,603,036 shares of the company’s stock, valued at approximately $11,878,496.76. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Acelyrin Company Profile

(Free Report)

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.

See Also

Want to see what other hedge funds are holding SLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acelyrin, Inc. (NASDAQ:SLRNFree Report).

Institutional Ownership by Quarter for Acelyrin (NASDAQ:SLRN)

Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter.